- Home
- BXP vs BBIO Comparison
BXP vs BBIO Comparison
Compare BXP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- BBIO
- Stock Information
- Founded
- BXP 1970
- BBIO 2015
- Country
- BXP United States
- BBIO United States
- Employees
- BXP N/A
- BBIO N/A
- Industry
- BXP Real Estate Investment Trusts
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BXP Real Estate
- BBIO Health Care
- Exchange
- BXP Nasdaq
- BBIO Nasdaq
- Market Cap
- BXP 11.4B
- BBIO 12.5B
- IPO Year
- BXP 1997
- BBIO 2019
- Fundamental
- Price
- BXP $73.00
- BBIO $71.90
- Analyst Decision
- BXP Buy
- BBIO Strong Buy
- Analyst Count
- BXP 17
- BBIO 19
- Target Price
- BXP $77.71
- BBIO $74.79
- AVG Volume (30 Days)
- BXP 1.5M
- BBIO 2.4M
- Earning Date
- BXP 10-28-2025
- BBIO 10-29-2025
- Dividend Yield
- BXP 3.85%
- BBIO N/A
- EPS Growth
- BXP N/A
- BBIO N/A
- EPS
- BXP N/A
- BBIO N/A
- Revenue
- BXP $3,425,025,000.00
- BBIO $353,780,000.00
- Revenue This Year
- BXP $2.83
- BBIO $123.32
- Revenue Next Year
- BXP $2.27
- BBIO $73.46
- P/E Ratio
- BXP N/A
- BBIO N/A
- Revenue Growth
- BXP 2.42
- BBIO 62.46
- 52 Week Low
- BXP $54.22
- BBIO $25.34
- 52 Week High
- BXP $84.75
- BBIO $72.26
- Technical
- Relative Strength Index (RSI)
- BXP 57.94
- BBIO 71.58
- Support Level
- BXP $68.46
- BBIO $64.41
- Resistance Level
- BXP $73.17
- BBIO $67.71
- Average True Range (ATR)
- BXP 1.56
- BBIO 2.80
- MACD
- BXP 0.30
- BBIO 0.35
- Stochastic Oscillator
- BXP 95.97
- BBIO 95.73
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.